Replidyne ends deal with Asubio

Tag : e antigen
Replidyne ends deal with Asubio, expects charge and GenentechAnnounces July 14 Webcast of Financial and Other Business Results

City of Industry, CA --(www.FinancialNewsUSA.com)-- 06/24/2008 -Healthcare industry news provided by Financial News USA (OTC:FNWU). Biotechnology company Replidyne Inc. (NASDAQ: RDYN) recentlysaid it ended a licensing deal with Asubio Pharma Co. for its leaddrug candidate and expects a charge of about $4.1 million. In May,Replidyne discontinued enrollment in a late-stage study testing itsfaropenem medoxomil oral antibiotic as a treatment for patientswith acute exacerbation of chronic bronchitis. The company made thedecision to terminate the deal Monday because it was unable tosecure a partner for the clinical program. It also ended a supplyagreement with Nippon Soda Co.Replidyne said the charges willinclude about $3.5 million in termination fees for Asubio and$600,000 in engineering costs for Nippon. Other payments going toNippon include $900,000 for delay compensation.

MDRNA, Inc. (NASDAQ: MRNA) announced recently that in accordancewith NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), the CompensationCommittee of the Board of Directors approved an inducement grant ofstock options to J. Michael French, MDRNAs Chief ExecutiveOfficer, in connection with the employment agreement that MDRNAentered into with Mr. French. On June 23, 2008, Mr. French wasgranted options to purchase up to 1,260,000 shares of Common Stock,of which options to purchase up to 160,037 shares of Common Stockwere granted under the Companys 2008 Stock Incentive Plan, andoptions to purchase up to 1,099,963 shares of Common Stock weregranted as employment inducement options.

Genentech, Inc. (NYSE: DNA) will announce its 2008 second quarterfinancial results on Monday, July 14, 2008, after the close of thefinancial markets. The announcement will be followed by a livewebcast with Genentech management at 1:45 p.m. Pacific Time. Thewebcast can be accessed on Genentech's web site at http://www.gene.com and will be archived and available for replay until 5:00 p.m.Pacific Time on August 4, 2008.

TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializingin the development of immunotherapeutics for cancer and vaccinesfor infectious diseases, announced that an independent third partyresearch article in the Journal of Investigative Dermatology hasconfirmed and corroborated that a TAP incorporated vaccine shouldbe considered as a therapy for the treatment of cancer, in thiscase, Melanoma. The article, in advance online publication 3 April2008, titled, "Restoration of the Expression of TransportersAssociated with Antigen Processing in Human Malignant MelanomaIncreases Tumor-Specific Immunity," is yet another promisingresearch study that confirms and corroborates the TAP incorporatedvaccine. There is now a vast amount of research data supporting andcorroborating the initial description of the promising effect ofTAP as a cancer therapy and their effect on tumor recognition. Formore information, please visit www.stocksjournal.com. About Financial News USA

Financial News USA is a Next Generation Financial Communicationsfirm focused on the distribution of market moving news. FinancialNews USA has developed leading edge e-publishing tools includingprogramming proprietary RSS feeds and enabling open source pressrelease publishing across its network. Financial News USA has beenaggressively expanding its news distribution network by targetingdirect feeds to financial news and data providers such asFinancialContent, Yahoo (NASDAQ: YHOO), among others. FinancialNews USA offers a free news feed available online(www.financialnewsusa.com) to websites and financial serviceslooking for content and for individual investors looking to stayinformed on the financial markets. Financial News USA and itsaffiliates charge each client cash for news distribution and maytake an equity position in the companies mentioned herein, pleasevisit the disclaimer at www.financialnewsusa.com.

Contact Information:
Financial News USA
Email: info@financialnewsusa.com